Immunome, Inc. IMNM

IMNM Company Overview

Immunome, Inc. is a U.S.-based biotechnology company focused on the discovery and development of targeted cancer therapies and antibody-based therapeutics. The company operates primarily within the oncology and immunotherapy sectors, with a strategic emphasis on radioligand therapies (RLTs), antibody-drug conjugates (ADCs), and precision biologics designed to address difficult-to-treat cancers. Immunome’s revenue has historically been derived from research collaborations, licensing arrangements, and financing activities, while its long-term strategy centers on advancing proprietary therapeutic candidates through clinical development.

The company evolved from an antibody discovery platform business into a more oncology-focused biotechnology developer through a series of acquisitions and portfolio expansions. A major strategic shift occurred following the acquisition of Morphimmune, which strengthened Immunome’s ADC capabilities, and the acquisition of Radiopharm Theranostics’ early-stage assets and related radioligand therapy programs. Immunome’s positioning is differentiated by its integration of antibody discovery technologies with targeted therapeutic delivery systems intended to improve efficacy and reduce systemic toxicity in oncology applications.